In vitro modelling of immune effector cell-associated neurotoxicity syndrome (ICANS) resulting from CAR T-cell therapy treating haematological cancer
Aisling McGarry, Shiden Solomon, Le Anh Luong, Lorenzo Veschini, Jemeen Sreedharan, Reuben Benjamin, Gerald Finnerty, Anna Schurich · FENS Forum 2024
Introduction of chimeric antigen receptor (CAR) T-cell therapy has transformed haematological cancer treatment by directing T cells to target tumour antigens e.g. CD19, inducing tumour cell death. However, its use is limited by neurotoxicity, most notably immune effector cell-associated neurotoxicity syndrome (ICANS). ICANS presents with wide-ranging neurological symptoms including seizures and altered consciousness, which can progress to coma and death. ICANS is linked to excessive cytokine release and blood-brain barrier dysfunction, yet its precise mechanisms remain unclear. We aim to eluci
ePoster · Neuroscience